+2,552.3%
AMD vs MRNA
+554.4%
+1,997.9%
-65.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.5% | +5.4% | -2.9% | +2.0% |
| 7D | +8.1% | -1.1% | +9.2% | +8.1% |
| 30D | +6.9% | +126.1% | -119.2% | -9.1% |
| 3M | +5.7% | +190.0% | -184.4% | -14.9% |
| 6M | +152.0% | +157.2% | -5.2% | +107.1% |
| YTD | +141.0% | +388.2% | -247.2% | +77.1% |
| 1Y | +231.6% | +467.0% | -235.5% | +135.6% |
| 3Y | +390.1% | +36.1% | +354.0% | +314.4% |
| 5Y | +390.6% | -68.0% | +458.6% | +374.4% |
| All | +2,552.3% | +554.4% | +1,997.9% | +1,490.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling